Bullish & Foolish
Full ALZN fundamentals All 466 on the Survival Watch

ALZNALZAMEND NEURO, INC.

Is Alzamend Neuro struggling financially?

Yes, by its own account. Alzamend Neuro told the SEC on 22 Jul 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Jul 2026

3/100

Critical

Sector
Biotech/Pharma
Market cap
$7.5M
Source filing
10-K 22 Jul 2026
Balance sheet
30 Apr 2026

Cash runway

  • 0months

    If the burn speeds up

    Empty by Apr 2026

  • 1month

    If it eases off

    Empty by May 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$711K

÷

Cash burned over the last 12 months

$14.0M

What Alzamend Neuro told the SEC

…to delay, reduce or eliminate our research and development programs or other operations. Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. Our independent registered public accounting firm has issued a report on our financial statements for the year ended April 30, 2026, that contains an emphasis of a matter paragraph…

ALZAMEND NEURO, INC., Form 10-K, filed 22 Jul 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 446.5% share-count increase The company issued stock. Each share now owns 81.7% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt